[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intrauterine-adhesion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intrauterine-adhesion":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,68,95,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100595442","intrauterine-stent-placement-following-hysteroscopic-septum-resection-100595442",false,"NCT07032506","Intrauterine Stent Placement Following Hysteroscopic Septum Resection","A Randomized Controlled Trial of Intrauterine Stent Placement Following Hysteroscopic Septum Resection","Inclusion Criteria:\n\n* Age 18 and above\n* Patients electing to undergo hysteroscopic septoplasty following an informed consent and shared decision making process\n* Uterine septum of at least 50% of the uterine cavity length as quantified on 3-dimensional saline infusion ultrasound\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent\n* History of prior uterine septum resection\n* History of prior transmural uterine surgery\n* Preexisting intrauterine adhesions or prior treatment for intrauterine adhesions\n* Individuals in whom complete septum resection is unable to be performed as a single procedure","FEMALE","18 Years",{"count":19,"type":20},320,"ESTIMATED","INTERVENTIONAL",[23],"NA","The study hopes to learn the best way to prevent internal scar tissue after septum removal. The use of an intrauterine foley catheter balloon may prevent the formation of adhesions following surgery.",[26],"Intrauterine Adhesion",[28,29,30,31],"intrauterine foley balloon catheter stent","uterine malformations","uterine septums","hysteroscopic septoplasty","RECRUITING","2026-06-11",{"date":35,"type":36},"2026-06-12","ACTUAL",{"date":38,"type":36},"2026-05-14",{"date":40,"type":20},"2031-12-31",{"name":42,"class":43},"Weill Medical College of Cornell University","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":65,"locationsCount":67},"100639961","to-evaluate-the-safety-and-effectiveness-of-intrauterine-adhesion-preventer-in-the-prevention-and-treatment-of-intrauterine-adhesions-a-prospective-multicenter-randomized-controlled-clinical-trial-100639961","NCT07611474","To Evaluate the Safety and Effectiveness of Intrauterine Adhesion Preventer in the Prevention and Treatment of Intrauterine Adhesions, a Prospective, Multicenter, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients clinically diagnosed with intrauterine adhesions and with surgical indications (referring to those with fertility requirements or obstructed menstrual blood drainage) ② Women aged 20-40 years old; ③ Subjects voluntarily participated in the trial and signed informed consent.\n\nExclusion Criteria:\n\n* ① Patients with obviously abnormal uterine cavity shape after surgery; those who could not clearly separate the normal uterine cavity anatomical morphology (i.e. bilateral or unilateral fallopian tube openings were not visible); those with reproductive organ malformations and uterine cavities that were too large or too small; those with recent uterine perforation; those with cervical insufficiency.\n\n  * Those with a history of intrauterine adhesions and treatment;\n\n    * Those with endometrial tuberculosis or suspected endometrial tuberculosis;\n\n      * Those with adenomyosis or uterine fibroids\\>4cm;\n\n        * Those with a history of malignant tumors or suspected malignant tumors;\n\n          * Those with acute and chronic intrauterine infection and genital infection;\n\n            * Those with unexplained vaginal bleeding or suspected uterine malignant lesions;\n\n              * Those with severe anemia and abnormal coagulation function; those with a history of thrombosis; ⑨ Those in the acute stage of various diseases or severe systemic diseases;\n\n                * Those with severe mental illness and physical weakness who cannot tolerate this operation;\n\n                  ⑪ Those with severe heart, liver, and kidney function diseases;\n\n                  ⑫ Those with contraindications to anesthesia or surgery;\n\n                  ⑬ Those who have participated in clinical trials in the past three months.\n                  * Those who are considered unsuitable for inclusion by the researchers.","20 Years","40 Years",{"count":54,"type":20},200,[23],"To evaluate the effect of uterine stents in preventing intrauterine adhesions after intrauterine operation and whether they meet the safety requirements for clinical use. The trial adopted a prospective, multicenter, randomized controlled, non-inferiority clinical trial design. The target population of the trial was 200 women aged 20-40 years with intrauterine adhesions and surgical indications (referring to those with fertility requirements or menstrual blood drainage obstruction), who were randomly divided into an experimental group and a control group, with 100 cases in each group. The experimental group was the group with intrauterine stents placed in the uterine cavity after hysteroscopic intrauterine adhesion separation surgery, and the control group was the group with intrauterine rings + balloons + sodium hyaluronate gel placed in the uterine cavity. After 3 courses of artificial cycles, the patients were hospitalized for hysteroscopy review.",[26,58],"Intrauterine Adhesions","2026-05-20",{"date":61,"type":36},"2026-05-28",{"date":63,"type":36},"2021-01-01",{"date":40,"type":20},{"name":66,"class":43},"The Third Xiangya Hospital of Central South University",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":67},"100625382","investigating-the-association-between-diagnostic-and-therapeutic-management-models-and-prognosis-of-intrauterine-adhesions-based-on-a-large-scale-prospective-cohort-study-100625382","NCT07421908","Investigating the Association Between Diagnostic and Therapeutic Management Models and Prognosis of Intrauterine Adhesions Based on a Large-Scale Prospective Cohort Study","Inclusion Criteria:\n\n* Patients with intrauterine adhesions diagnosed and treated in our hospital and the sub-central units of this project: aged 18-45 years old; The collection began after the ethical review was passed. A total of 5,000 cases were collected, and 2,000 cases were collected in this center.\n\nExclusion Criteria:\n\n* Abnormal ovarian function, male infertility, inability to cooperate with diagnosis and treatment and follow-up visits",true,"45 Years",{"count":77,"type":20},5000,[23],"This research plan aims to explore a new diagnosis and treatment management model for intrauterine adhesions and verify its efficacy and feasibility through a multicenter real-world study. Intrauterine adhesions are a common gynecological disease that may affect women's fertility. The study will focus on several key issues:\n\n1. How do three-dimensional ultrasound image features reflect the diagnosis and prognosis of intrauterine adhesions;\n2. The effect of new diagnostic and treatment technologies (such as cold knife plowing technology and patented intrauterine stents) in preventing the recurrence of intrauterine adhesions\n3. The efficacy of traditional Chinese medicine prescriptions in promoting endometrial growth and preserving pregnancy;\n4. How to construct a postoperative infertility risk prediction model that combines multidimensional risk factors of traditional Chinese and Western medicine.\n\nTo achieve these goals, the study will:\n\n1. Establish four-dimensional ultrasound diagnostic evaluation standards to improve the accuracy of diagnosis;\n2. Build a large database and data cohort, standardize the diagnosis and treatment standards, and provide solid data support for the research;\n3. Evaluate the efficacy of the new model through real-world research, and compare the clinical efficacy of the new diagnosis and treatment model with the traditional diagnosis and treatment model;\n4. Construct and verify the postoperative infertility risk prediction model to provide clinicians with a visual display of risk prediction for clinical application.\n\nThis study is expected to provide a scientific basis for improving the treatment effect of intrauterine adhesions and reducing the infertility rate, and promote the standardization and standardization of the diagnosis and treatment model of combining traditional Chinese and Western medicine, bringing good news to more patients with intrauterine adhesions.",[26],[82,83,84,85,86],"Hysteroscopy","ploughing technique","cold scissors","Gland density","multi-center study","2026-02-11",{"date":89,"type":36},"2026-02-19",{"date":91,"type":36},"2025-03-01",{"date":93,"type":20},"2035-03-01",{"name":66,"class":43},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100459022","heparin-solution-versus-anti-adhesion-barrier-gel-for-intrauterine-adhesions-prevention-after-operative-hysteroscopy-100459022","NCT05257213","Heparin Solution Versus Anti-adhesion Barrier Gel for Intrauterine Adhesions Prevention After Operative Hysteroscopy","Intrauterine Adhesions Prevention: the Use of Heparin Solution Compared to Application of Anti-adhesion Barrier Gel After Operative Hysteroscopy","Inclusion Criteria:\n\n* female sex\n* indication for operative hysteroscopy including one or more of the following:\n* infertility,\n* irregular bleeding,\n* oligo-\u002Famenorrhea,\n* Asherman syndrome,\n* G0-G3 fibroids,\n* dysmorphic uterus.\n\nExclusion Criteria:\n\n* ongoing pregnancy,\n* genital cancer,\n* pelvic inflammatory disease,\n* excessive uterine bleeding.","25 Years","50 Years",{"count":105,"type":20},100,[23],"The aim of this study is to compare the efficacy of intrauterine application of heparin solution to the use of hyaluronic acid barrier gel for the prevention of intrauterine adhesion formation after operative hysteroscopy.",[26],[110,111,112,113,114],"operative hysteroscopy","heparin","anti-adhesion barrier gel","intrauterine adhesion","hyaluronic acid","2025-05-20",{"date":117,"type":36},"2025-05-21",{"date":119,"type":36},"2022-02-14",{"date":121,"type":20},"2026-02-28",{"name":123,"class":43},"Nadezhda Women's Health Hospital",2,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":67},"100565684","application-of-platelet-rich-plasma-prp-in-reproductive-medicine-100565684","NCT06645379","Application of Platelet-rich Plasma (PRP) in Reproductive Medicine","Inclusion Criteria:\n\n* Premature ovarian insufficiency: ① Women aged \\>18 and \\\u003C40 years old; ② Oligomenorrhea or amenorrhea for more than 4 months (excluding pregnancy); ③ Basal follicle stimulating hormone (FSH) \\>25IU\u002FL (interval \\>4 weeks) at least 2 times, or total antral follicles (AFC) \\\u003C5, or anti-Mullerian hormone (AMH) \\\u003C1.1ng\u002FmL.\n* Poor ovarian response: ① Advanced age (≥40 years) or other risk factors for poor ovarian response; ② Poor ovarian response in previous IVF cycle, with ≤3 oocytes retrieved using conventional protocols; ③ Decreased ovarian reserve (antral follicle count \\\u003C5\\~7 or anti-Müllerian hormone \\\u003C0.5\\~1.1 ug\u002FL). Meeting any 2 of the above 3 criteria is sufficient.\n* Intrauterine adhesion: ① Diagnosed by hysteroscopy and scored ≥5 points according to the American Fertility Society criteria (1988); ② With symptoms such as reduced menstrual flow amenorrhea, periodic lower abdominal pain, infertility, or recurrent miscarriage; ③ Adult women with the desire to conceive.\n* Thin endometium: ①Endometrial thickness \\\u003C7mm on ovulation day or on the day of human chorionic gonadotropin (HCG) injection, or \\\u003C7mm on progesterone conversion day when using conventional hormone replacement therapy, ②adult women with the desire to comceive.\n* Repeated implantation failure: Women under 40 years old who have failed to achieve clinical pregnancy after transplanting at least three high-quality embryos within three fresh or frozen cycles. High-quality embryos include: Day 3 embryos (with ≥8 cells, evenly sized blastomeres, and \\\u003C10% fragmentation) and blastocysts (≥3BB).\n\nExclusion Criteria:\n\n* Alanine aminotransferase \\> 3 times the normal upper limit or estimated glomerular filtration rate (EGFR) \\\u003C 90 ml\u002Fmin;\n* Suffering from hemorrhagic diseases (such as hemophilia) or taking anticoagulant or antiplatelet drugs;\n* Suffering from serious mental illness, cardiovascular and cerebrovascular diseases and malignant tumors;\n* Suffering from diabetes with poor blood sugar control or other systemic diseases;\n* Drug abuse, alcoholism or drug addiction;\n* Participated in other interventional clinical studies within half a year;\n* Poor compliance;\n* Other circumstances that are not suitable for participating in the study.",{"count":132,"type":20},300,[23],"Female fertility is affected by many factors, such as ovarian function, fallopian tube patency, uterine environment, and mental state, among which the ovaries and endometrium are more important. In reproductive medicine, ovarian dysfunction, poor ovarian reaction, intrauterine adhesion, recurrent implantation failure, and thin endometrium are the five most common diseases that affect fertility. These five diseases lack effective treatment, and previous studies have shown that platelet-rich plasma is promising in treating these five diseases, so it is necessary to further explore the therapeutic effect and potential mechanism.",[136,26,137,138,139],"Premature Ovarian Insufficiency","Poor Ovarian Response","Repeated Implantation Failure","Thin Endometrium","2025-02-14",{"date":142,"type":36},"2025-02-18",{"date":144,"type":36},"2024-10-17",{"date":146,"type":20},"2027-09-15",{"name":148,"class":43},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine"]